KAYTUS
23.5.2024 17:14:31 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, unveiled the KR2280V2 2U, 2-socket flagship server at ISC High Performance 2024. This powerhouse server supports the 4th/5th Gen Intel® Xeon®, 4th Gen AMD EPYCTM, and AmpereOne® processors, offering an impressive array of storage combinations with up to 20 LFF drives, 45 SFF drives, or 24 E3.S SSDs. When upgraded with CXL modules, the KR2280V2 horizontally expands to 16 DIMMs, effortlessly meeting the demands of memory-intensive applications. Its innovative front I/O configuration delivers remarkable scalability, supporting up to 20 PCIe 5.0 devices, setting a new benchmark in performance. With its flexible compute capabilities and adaptable storage and I/O designs, the KR2280V2 is engineered to accommodate a wide spectrum of business needs— ranging from general computing to accelerated computing, and from massive storage capacity to high-performance I/O-oriented applications. This versatility makes it the ultimate solution for diverse application scenarios, ensuring consistent and efficient operation and maintenance.
Revolutionizing Diverse Applications Scenarios with Versatile Compute Power
To deliver the best computing solutions for diverse scenarios, the IT architecture of data centers is rapidly evolving and becoming increasingly sophisticated. As business needs diversify, a single chip can no longer meet the demands of complex, high-efficiency computing, leading to the emergence of various acceleration chips. This rapid evolution places new demands on processors' energy efficiency and core performance. The KR2280V2 boldly rises to this challenge by supporting three major computing platforms: Intel® Xeon®, AMD EPYC™, and AmpereOne®. This versatility offers a wide range of computing power options, perfectly tailored for different scenarios. By unifying management interfaces, the KR2280V2 dramatically reduces operation and maintenance pressure in heterogeneous computing configurations, making it exceptionally user-friendly and efficient.
Unparalleled Configuration Flexibility Optimized for Peak Application Performance
Through highly advanced modularization, KR2280V2 enables dynamic configurations of storage, I/O, and acceleration modules, offering an impressive array of over 100 configurations. This versatility seamlessly adapts to various scenarios, from general computing to cutting-edge heterogeneous computing, from storage-intensive to blazing-fast I/O-intensive applications, and from traditional rear I/O maintenance to innovative front I/O maintenance design. When it comes to energy efficiency, the KR2280V2 leads the way with its fully compatible cold-plated liquid cooling design, enhanced with state-of-the-art leakage detection mechanisms and bolstered system reliability.
Industry's First to Achieve BSI Cryptographic Uncompromising Security Encryption
The cryptographic module employed in KR2280V2's BMC out-of-band management module establishes a new security benchmark. It adheres fully to the stringent ISO/IEC 19790:2012 requirements, delivering excellence across role permissions, service and authentication, software/firmware security, operating environment security, and full-process self-inspection. Simultaneously, it ensures an end-to-end security system through the integration of state-of-the-art technologies. From dual flash chips to BMC self-recovery mechanisms, comprehensive access control, and multiple authentications, every aspect is meticulously designed to safeguard critical business data with uncompromising encryption. The KR2280V2 sets the standard for data security in the digital age.
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523414563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom